Syndax Pharmaceuticals (Nasdaq:SNDX) - Aandelenkoers, Nieuws & Analyse

SNDX Overzicht aandelen

Syndax Pharmaceuticals, Inc., een biofarmaceutisch bedrijf in een klinische fase, ontwikkelt therapieën voor de behandeling van kanker.

Over het bedrijf

SNDX fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Revenue is forecast to grow 51.43% per year

Risicoanalyse

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Does not have meaningful revenue ($4M)

Syndax Pharmaceuticals, Inc. Concurrenten

Inhibrx

NasdaqGM:INBX

US$1.8b

Vir Biotechnology

NasdaqGS:VIR

US$1.3b

Viridian Therapeutics

NasdaqCM:VRDN

US$1.7b

Keros Therapeutics

NasdaqGM:KROS

US$2.2b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Syndax Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	US$18.98
52 Week Hoogtepunt	US$25.34
52 Week Laag	US$13.14
Bèta	0.91
11 maand verandering	0.85%
3 maanden verandering	-4.62%
1 Jaar Verandering	31.81%
33 jaar verandering	8.46%
5 jaar verandering	171.92%
Verandering sinds IPO	58.04%

Recent nieuws en updates

We Think Syndax Pharmaceuticals (NASDAQ:SNDX) Needs To Drive Business Growth Carefully

Oct 14

Syndax Pharmaceuticals: Navigating Through A Pivotal Year

Sep 20

Recent updates

We Think Syndax Pharmaceuticals (NASDAQ:SNDX) Needs To Drive Business Growth Carefully

Oct 14

Syndax Pharmaceuticals: Navigating Through A Pivotal Year

Sep 20

Syndax: Gearing Up For Launches

Jun 21

Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

Jun 20

Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope

Mar 28

Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation

Mar 04

Is Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Trading At A 46% Discount?

Nov 20

Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

Sep 27

Syndax Pharmaceuticals Q2 2022 Earnings Preview

Aug 07

Syndax Pharmaceuticals: Cash-Rich With 2 Promising Drugs

Apr 08

Rendement voor aandeelhouders

	SNDX	US Biotechs	US Markt
7D	-1.2%	-0.7%	-1.6%
1Y	31.8%	19.8%	30.8%

Rendement versus industrie: SNDX exceeded the US Biotechs industry which returned 19.8% over the past year.

Rendement versus markt: SNDX matched the US Market which returned 30.8% over the past year.

Prijsvolatiliteit

Is SNDX's price volatile compared to industry and market?
SNDX volatility
SNDX Average Weekly Movement	5.2%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: SNDX has not had significant price volatility in the past 3 months compared to the US market.

Volatiliteit in de loop van de tijd: SNDX's weekly volatility (5%) has been stable over the past year.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2005	184	Michael Metzger	www.syndax.com

Syndax Pharmaceuticals, Inc, een biofarmaceutisch bedrijf in een klinische fase, ontwikkelt therapieën voor de behandeling van kanker. De belangrijkste productkandidaten zijn revumenib, een krachtige, selectieve remmer van de menin-MLL bindingsinteractie voor de behandeling van KMT2A-heringedeelde acute leukemieën en solide tumoren; en SNDX-6352 of axatilimab, een monoklonaal antilichaam dat de colony stimulating factor 1, of CSF-1 receptor blokkeert voor de behandeling van patiënten met chronische graft versus host disease (cGVHD) en idiopathische longfibrose (IPF). Het bedrijf ontwikkelt ook Entinostat.

Syndax Pharmaceuticals, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Syndax Pharmaceuticals zich tot de beurswaarde?
SNDX fundamentele statistieken
Marktkapitalisatie	US$1.62b
Inkomsten(TTM)	-US$264.08m
Inkomsten(TTM)	US$3.50m

461.5x

P/S-verhouding

-6.1x

Koers/Winstverhouding

Is SNDX overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
SNDX resultatenrekening (TTM)
Inkomsten	US$3.50m
Kosten van inkomsten	US$34.34m
Brutowinst	-US$30.84m
Overige uitgaven	US$233.24m
Inkomsten	-US$264.08m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Nov 05, 2024

Winst per aandeel (EPS)	-3.10
Brutomarge	-881.23%
Nettowinstmarge	-7,545.20%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde SNDX op de lange termijn?

Bekijk historische prestaties en vergelijking

SNDX Overzicht aandelen

Beloningen

Risicoanalyse

Syndax Pharmaceuticals, Inc. Concurrenten

NasdaqGM:INBX

US$1.8b

NasdaqGS:VIR

US$1.3b

NasdaqCM:VRDN

US$1.7b

NasdaqGM:KROS

US$2.2b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Syndax Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 05, 2024

We Think Syndax Pharmaceuticals (NASDAQ:SNDX) Needs To Drive Business Growth Carefully

Syndax Pharmaceuticals: Navigating Through A Pivotal Year

Incyte and Syndax Pharmaceuticals Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Consensus revenue estimates fall by 21%

Syndax Announces Pdufa Action Date Extension for Revumenib Nda for Relapsed or Refractory Kmt2ar Acute Leukemia

Recent updates

Syndax Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 05, 2024

We Think Syndax Pharmaceuticals (NASDAQ:SNDX) Needs To Drive Business Growth Carefully

Syndax Pharmaceuticals: Navigating Through A Pivotal Year

Incyte and Syndax Pharmaceuticals Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Consensus revenue estimates fall by 21%

Syndax Announces Pdufa Action Date Extension for Revumenib Nda for Relapsed or Refractory Kmt2ar Acute Leukemia

Syndax Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 3000 Value Index

Consensus revenue estimates increase by 12%

Syndax: Gearing Up For Launches

Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

SSyndax Pharmaceuticals, Inc. Presents Updated Positive Data from BEAT AML and Augment-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress

Syndax Pharmaceuticals Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC

Syndax Pharmaceuticals, Inc. Announces Board Changes

Syndax Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Syndax Pharmaceuticals, Inc. Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session

Syndax Pharmaceuticals, Inc., Annual General Meeting, May 15, 2024

Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia

Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope

Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia

Syndax Pharmaceuticals, Inc. Announces Executive Changes

Consensus EPS estimates fall by 23%

Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation

Syndax Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Syndax Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $199.999985 million.

Syndax Pharmaceuticals Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting

Incyte and Syndax Pharmaceuticals Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

Is Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Trading At A 46% Discount?

Syndax Pharmaceuticals Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual Meeting

Syndax Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Syndax Pharmaceuticals Announces to Initiate Nda Submission of Revumenib in Relapsed/Refractory Kmt2ar Acute Leukemia Under Fda's Real-Time Oncology Review Program

Syndax Pharmaceuticals Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stated Interim Analysis

Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

Director notifies of intention to sell stock

Syndax Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Syndax Pharmaceuticals and Incyte Announce Positive Topline Results from the Pivotal Agave-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

Director notifies of intention to sell stock

Consensus revenue estimates decrease by 11%, EPS upgraded

Director exercised options and sold US$715k worth of stock

Director exercised options and sold US$794k worth of stock

Syndax Pharmaceuticals, Inc. Announces Executive Changes

President exercised options and sold US$695k worth of stock

President exercised options and sold US$853k worth of stock

Consensus EPS estimates fall by 21%

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

President exercised options and sold US$1.1m worth of stock

Price target increased by 7.6% to US$34.44

Independent Director exercised options and sold US$616k worth of stock

Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology

Co-Founder & Chief Scientific Officer exercised options and sold US$467k worth of stock

Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer

Insufficient new directors

Consensus revenue estimates increase by 64%

Third quarter 2022 earnings released: US$0.58 loss per share (vs US$0.40 loss in 3Q 2021)

Syndax Pharmaceuticals, Inc. Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of Augment-101 Trial of Revumenib in Patients with Acute Leukemias

Syndax Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

CEO & Director exercised options and sold US$549k worth of stock

President exercised options and sold US$4.4m worth of stock

Co-Founder & Chief Scientific Officer exercised options and sold US$468k worth of stock